Your session is about to expire
← Back to Search
Combination Therapy for Multiple Myeloma
Study Summary
This trial is testing a new combination drug treatment for multiple myeloma, a cancer of the blood.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am HIV positive.I have been cancer-free from any other cancer for more than 2 years.I have tested positive for hepatitis B recently.I am allergic to belantamab mafodotin, daratumumab, bortezomib, boron, mannitol, or similar drugs.My liver condition is currently unstable.You have a certain amount of abnormal proteins in your blood or urine.I have had a stem cell transplant from a donor.I am using birth control as required by local laws for clinical study participants.I had a stem cell transplant or BCMA therapy over 100 days ago, with no current infections and my organs work well.I have a heart condition.I have symptoms of amyloidosis, POEMS syndrome, or plasma cell leukemia currently.I have a mild eye surface condition, not severe.I do not have active brain disease, blood cancer, or amyloidosis symptoms.I am currently being treated for an infection.My side effects from previous treatments are mild, except for possible moderate nerve pain.I am currently experiencing active bleeding.I have multiple myeloma and previous treatments, including specific antibodies and inhibitors, didn't work.I haven't had myeloma treatment or plasmapheresis in the last 2 weeks.I have not had any major surgery in the last four weeks.I haven't taken high dose steroids in the last 14 days.I am not taking strong medications that affect drug transport in my body.You have tested positive for hepatitis C within the last 3 months before starting the study.I am 18 years old or older.I have kidney issues, but my protein levels are okay.I can take care of myself and am up and about more than half of the day.
- Group 1: Arm A
- Group 2: Arm B
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the maximum number of participants allowed in this research endeavor?
"Affirmative, based on the information published on clinicaltrials.gov, this research trial is currently recruiting participants. This study was initially posted in early January and recently updated at the end of month. The team intends to enroll 64 individuals from a single location."
What is the primary aim of this clinical research?
"This medical trial's primary outcome, which is to be monitored for up to 12 weeks, entails evaluating the overall incidence and intensity of adverse events in a dose escalation experiment. Secondary objectives comprise measuring the time until progression of symptoms, analyzing cytokine profile data (such as IL-4, CXCL10 (IP-10), etc.), and assessing Progression Free Survival - or how long it takes for study drugs to control disease development."
Are there any slots available for prospective participants in this clinical trial?
"According to information stored on clinicaltrials.gov, this trial is actively searching for participants with the initial post-date set at January 1st 2022 and latest edit logged as of January 24th 2022."
What medical condition is Belantamab Mafodotin, Cyclophosphamide and Dexamethasone commonly prescribed for?
"Belantamab Mafodotin, Cyclophosphamide and Dexamethasone are frequently prescribed to treat synovitis. This potent mix can also be used for ophthalmia, sympathetic pathologies, lung cancers, as well as branch retinal vein occlusion."
To what extent has Belantamab Mafodotin, Cyclophosphamide and Dexamethasone been tested as part of other clinical trials?
"Presently, 1293 trials are evaluating Belantamab Mafodotin, Cyclophosphamide and Dexamethasone. Of these studies, 268 are in their concluding phase 3. Despite the majority of research being conducted around Philadelphia Pennsylvania, a total 41370 locations have active clinical trials for this drug combination."
Share this study with friends
Copy Link
Messenger